Biologics represented 5% of the drugs prescribed in the U.S. in 2024, but they accounted for more than half of the country’s ...

FDA aims to speed biosimilar approvals to increase competition, but experts warn drug prices may not drop quickly.

As biologic options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works ...

A novel oral therapy that inhibits the interleukin-23 inflammatory pathway provided control of moderate-to-severe psoriasis ...